Your request has been received.
We will send you more information as it becomes available.
days to go: ASP+6% CMS reimbursement for proven non-opioids used in all outpatient surgical settings is coming January 1, 2025.
The pMVL technology and versatility of administration enables infiltration into the surgical site to produce local analgesia, in the fascial plane to produce regional analgesia as a regional field block or as an interscalene brachial plexus nerve block. EXPAREL may be used across surgical procedures and has demonstrated improved clinical and economic outcomes.
to deliver controlled levels of bupivacaine1
bupivacaine in a suspension of multivesicular liposomes
of naturally occurring, biocompatible lipids2-4
bupivacaine over time1
ASP, average sales price; CMS, Centers for Medicare and Medicaid Services.
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older and regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and an adductor canal block. Safety and efficacy have not been established in other nerve blocks.
Please refer to full Prescribing Information.
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration
This website uses cookies to give you a better browsing experience. By clicking the "Allow all cookies" button, you agree to our use of cookies. For additional information, see our Cookie Notice.